Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03215381 | AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers | PHASE1 | COMPLETED | 8 | — | — | Oct 10, 2017 | Feb 19, 2018 | Feb 26, 2018 | 1 | Sweden |
To assess if 11C AZD1390 crosses the blood brain barrier in healthy volunteers
| Arm | Type | Description |
|---|---|---|
| [11C]AZD1390 Microdose | OTHER | \[11C\]AZD1390 single dose not exceeding 10 ug by IV bolus |
| Name | Type | Description |
|---|---|---|
| [11C]AZD1390 | DRUG | \[11C\]AZD1390 |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures. * Healthy Male subjects, aged 20 to 65 years (inclusive). * Subject should be healthy as determined by medical history, physical examination, laboratory parameters, ECG and brain MR...